DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer

Abstract

In conclusion, our data suggest that <b>BRAF^V600E</b> driven colorectal cancers have fragmented mitochondria which confers glycolytic phenotype and growth advantage to these tumors, and such phenotype is dependent at least in part on <b>PDK1</b>- thus highlighting a potential therapeutic target.